Belarus vs Cambodia: HIV/AIDS deaths averted by antiretroviral therapy
Belarus
1,203 deaths
in 2022
Cambodia
1,355 deaths
in 2024
Belarus rank
71st
Cambodia rank
68th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Belarus
- Cambodia
How they compare
Cambodia currently reports 1,355 deaths against 1,203 deaths in Belarus, a difference of 152 deaths.
That makes Cambodia's figure about 1.1 times Belarus's.
Across all 33 years both countries report, Cambodia has been ahead every year.
Belarus ranks 71st and Cambodia ranks 68th of 157 countries.
Cambodia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Belarus | Cambodia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 70.2 deaths | 1,701 deaths | 1,631 deaths | Cambodia |
| 2010s | 703.4 deaths | 3,140 deaths | 2,437 deaths | Cambodia |
| 2020s | 1,184 deaths | 1,706 deaths | 522.7 deaths | Cambodia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Belarus or Cambodia?
- Cambodia, at 1,355 deaths against 1,203 deaths in Belarus as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Belarus and Cambodia?
- 152 deaths, with Cambodia ahead.
- How many years of comparable data are there for Belarus and Cambodia?
- 33 years are reported by both, from 1990 to 2022.
- How do Belarus and Cambodia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Belarus ranks 71st and Cambodia ranks 68th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.